185 related articles for article (PubMed ID: 9345019)
1. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years.
Najean Y; Rain JD
Blood; 1997 Nov; 90(9):3370-7. PubMed ID: 9345019
[TBL] [Abstract][Full Text] [Related]
2. Risk of leukaemia, carcinoma, and myelofibrosis in 32P- or chemotherapy-treated patients with polycythaemia vera: a prospective analysis of 682 cases. The "French Cooperative Group for the Study of Polycythaemias".
Najean Y; Rain JD; Dresch C; Goguel A; Lejeune F; Echard M; Grange MJ
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():111-9. PubMed ID: 8951781
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of polycythemia. II.--Comparison of hydroxyurea with pipobroman in 294 patients less than 65 years of age].
Najean Y; Rain JD; Lejeune F; Echard M; Fermand JP; Gruyer P; Brahimi S
Ann Med Interne (Paris); 1998 Mar; 149(2):94-100. PubMed ID: 11490531
[TBL] [Abstract][Full Text] [Related]
4. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980.
Kiladjian JJ; Chevret S; Dosquet C; Chomienne C; Rain JD
J Clin Oncol; 2011 Oct; 29(29):3907-13. PubMed ID: 21911721
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of polycythemia vera with hydroxyurea or pipobroman. Efficacy and toxicity analysed from a protocol of 96 patients under 65 years of age. Le Groupe d'Etude des Polyglobulies].
Najean Y
Presse Med; 1992 Nov; 21(37):1753-7. PubMed ID: 1488420
[TBL] [Abstract][Full Text] [Related]
6. Treatment of polycythemia vera: use of 32P alone or in combination with maintenance therapy using hydroxyurea in 461 patients greater than 65 years of age. The French Polycythemia Study Group.
Najean Y; Rain JD
Blood; 1997 Apr; 89(7):2319-27. PubMed ID: 9116275
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of pipobroman in the treatment of polycythemia vera: long-term results in 163 patients.
Passamonti F; Brusamolino E; Lazzarino M; Baraté C; Klersy C; Orlandi E; Canevari A; Castelli G; Merante S; Bernasconi C
Haematologica; 2000 Oct; 85(10):1011-8. PubMed ID: 11025590
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcomes of polycythemia vera patients treated with pipobroman as initial therapy.
Kiladjian JJ; Gardin C; Renoux M; Bruno F; Bernard JF
Hematol J; 2003; 4(3):198-207. PubMed ID: 12764352
[TBL] [Abstract][Full Text] [Related]
9. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
[TBL] [Abstract][Full Text] [Related]
10. Polycythemia vera treated with pipobroman as single agent: low incidence of secondary leukemia in a cohort of patients observed during 20 years (1971-1991).
Petti MC; Spadea A; Avvisati G; Spadea T; Latagliata R; Montefusco E; Cosenza M; Malagnino F
Leukemia; 1998 Jun; 12(6):869-74. PubMed ID: 9639413
[TBL] [Abstract][Full Text] [Related]
11. Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea.
Boivin P
Nouv Rev Fr Hematol (1978); 1993; 35(5):491-8. PubMed ID: 8295823
[TBL] [Abstract][Full Text] [Related]
12. A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study.
Barbui T; Vannucchi AM; Finazzi G; Finazzi MC; Masciulli A; Carobbio A; Ghirardi A; Tognoni G
Am J Hematol; 2017 Nov; 92(11):1131-1136. PubMed ID: 28699191
[TBL] [Abstract][Full Text] [Related]
13. Efficacy trial of pipobroman in polycythemia vera and incidence of acute leukemia.
Brusamolino E; Salvaneschi L; Canevari A; Bernasconi C
J Clin Oncol; 1984 Jun; 2(6):558-61. PubMed ID: 6374054
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of polycythemia. I--Using radiophosphorus with or without treatment in 483 patients over 65 years of age].
Najean Y; Rain JD; Goguel A; Grange MJ; Vigneron N; Dupuy E; Mougeot-Martin M
Ann Med Interne (Paris); 1998 Mar; 149(2):87-93. PubMed ID: 11490530
[TBL] [Abstract][Full Text] [Related]
15. Can pegylated interferon improve the outcome of polycythemia vera patients?
Crisà E; Cerrano M; Beggiato E; Benevolo G; Lanzarone G; Manzini PM; Borchiellini A; Riera L; Boccadoro M; Ferrero D
J Hematol Oncol; 2017 Jan; 10(1):15. PubMed ID: 28086927
[TBL] [Abstract][Full Text] [Related]
16. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
17. Polycythemia vera and hydroxyurea resistance/intolerance: a monocentric retrospective analysis.
Demuynck T; Verhoef G; Delforge M; Vandenberghe P; Devos T
Ann Hematol; 2019 Jun; 98(6):1421-1426. PubMed ID: 30919072
[TBL] [Abstract][Full Text] [Related]
18. Treatment of polycythaemia vera and essential thrombocythaemia.
Tefferi A; Silverstein MN
Baillieres Clin Haematol; 1998 Dec; 11(4):769-85. PubMed ID: 10640216
[TBL] [Abstract][Full Text] [Related]
19. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion.
Sterkers Y; Preudhomme C; Laï JL; Demory JL; Caulier MT; Wattel E; Bordessoule D; Bauters F; Fenaux P
Blood; 1998 Jan; 91(2):616-22. PubMed ID: 9427717
[TBL] [Abstract][Full Text] [Related]
20. Treatment of polycythemia vera and essential thrombocythemia: the role of pipobroman.
Passamonti F; Lazzarino M
Leuk Lymphoma; 2003 Sep; 44(9):1483-8. PubMed ID: 14565648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
